Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis
Open Access
- 31 May 2018
- journal article
- review article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 47 (Suppl. 1), 14-29
- https://doi.org/10.1159/000481634
Abstract
Background: Focal segmental glomerulosclerosis (FSGS) is a histologic pattern of injury demonstrated by renal biopsy that can arise from a diverse range of causes and mechanisms. It has an estimated incidence of 7 per 1 million and is the most common primary glomerular disorder leading to end-stage renal disease in the United States. This review focuses on damage to the podocyte and the consequences of this injury in patients with FSGS, the genetics of FSGS, and approaches to treatment with a focus on the effects on podocytes. Summary: The podocyte is central to the glomerular filtration barrier and is particularly vulnerable because of its highly differentiated post-mitotic phenotype. The progressive structural changes involved in the pathology of FSGS include podocyte foot process effacement, death of podocytes and exposure of the glomerular basement membrane, filtration of nonspecific plasma proteins, expansion of capillaries, misdirected filtration at points of synechiae, and mesangial matrix proliferation. Although damage to and death of podocytes can result from single-gene disorders, evidence also suggests a role for soluble factors, such as soluble urokinase-type plasminogen activator receptor, cardiotrophin-like cytokine-1, and anti-CD40 antibodies, that promote FSGS recurrence post transplant. Several classes of medications, including corticosteroids, calcineurin inhibitors, endothelin receptor antagonists, adrenocorticotropic hormone, and rituximab, have been shown to be effective for the treatment of FSGS and have been demonstrated to have significant protective effects on podocytes. Key Messages: Greater understanding of podocyte biology is essential to the identification of new treatment targets and medications for the management of patients with FSGS.Keywords
This publication has 101 references indexed in Scilit:
- Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanismsKidney International, 2013
- Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1Nature Medicine, 2013
- Resolution of Recurrent Focal Segmental Glomerulosclerosis after RetransplantationThe New England Journal of Medicine, 2012
- Focal Segmental GlomerulosclerosisThe New England Journal of Medicine, 2011
- Target Organ Damage in African American Hypertension: Role of APOL1Current Hypertension Reports, 2011
- Clinical trial of focal segmental glomerulosclerosis in children and young adultsKidney International, 2011
- Wnt/β-Catenin Pathway in Podocytes Integrates Cell Adhesion, Differentiation, and SurvivalPublished by Elsevier BV ,2011
- Prevention and treatment of systemic glucocorticoid side effectsInternational Journal of Dermatology, 2010
- Autophagy fights disease through cellular self-digestionNature, 2008
- Pathophysiology of focal segmental glomerulosclerosisPediatric Nephrology, 2007